These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 18065788

  • 1. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study.
    Melamed ML, Eustace JA, Plantinga LC, Jaar BG, Fink NE, Parekh RS, Coresh J, Yang Z, Cantor T, Powe NR.
    Nephrol Dial Transplant; 2008 May; 23(5):1650-8. PubMed ID: 18065788
    [Abstract] [Full Text] [Related]

  • 2. Elevated parathyroid hormone predicts mortality in dialysis patients undergoing valve surgery.
    Yan H, Sharma J, Weber CJ, Guyton RA, Perez S, Thourani VH.
    Surgery; 2011 Dec; 150(6):1095-101. PubMed ID: 22136827
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Novel parathyroid hormone (1-84) assay as basis for parathyroid hormone monitoring in renal hyperparathyroidism.
    Kaczirek K, Prager G, Riss P, Wunderer G, Asari R, Scheuba C, Bieglmayer C, Niederle B.
    Arch Surg; 2006 Feb; 141(2):129-34; discussion 134. PubMed ID: 16490888
    [Abstract] [Full Text] [Related]

  • 5. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK.
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [Abstract] [Full Text] [Related]

  • 6. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients.
    Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH.
    Am J Kidney Dis; 2002 Jun; 39(6):1245-54. PubMed ID: 12046038
    [Abstract] [Full Text] [Related]

  • 7. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
    Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM.
    Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
    [Abstract] [Full Text] [Related]

  • 8. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism.
    Sanadgol H, Bayani M, Mohammadi M, Bayani B, Mashhadi MA.
    Iran J Kidney Dis; 2011 Nov; 5(6):410-5. PubMed ID: 22057074
    [Abstract] [Full Text] [Related]

  • 9. Are PTH serum levels predictive of coronary calcifications in haemodialysis patients?
    Coen G, Manni M, Mantella D, Pierantozzi A, Balducci A, Condò S, DiGiulio S, Yancovic L, Lippi B, Manca S, Morosetti M, Pellegrino L, Simonetti G, Gallucci MT, Splendiani G.
    Nephrol Dial Transplant; 2007 Nov; 22(11):3262-7. PubMed ID: 17597083
    [Abstract] [Full Text] [Related]

  • 10. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM.
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [Abstract] [Full Text] [Related]

  • 11. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism.
    Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC.
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):533-8. PubMed ID: 18782355
    [Abstract] [Full Text] [Related]

  • 12. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, Rodríguez-Puyol D, Cannata-Andía JB.
    Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
    [Abstract] [Full Text] [Related]

  • 13. The clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patients.
    Eren PA, Turan K, Berber I, Canbakan M, Kara M, Tellioglu G, Bugan U, Sevinç C, Turkmen F, Titiz MI.
    Clin Nephrol; 2009 Aug; 72(2):114-21. PubMed ID: 19640368
    [Abstract] [Full Text] [Related]

  • 14. Comparison between whole and intact parathyroid hormone assays.
    Taniguchi M, Tanaka M, Hamano T, Nakanishi S, Fujii H, Kato H, Koiwa F, Ando R, Kimata N, Akiba T, Kono T, Yokoyama K, Shigematsu T, Kakuta T, Kazama JJ, Tominaga Y, Fukagawa M.
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():42-9. PubMed ID: 21595852
    [Abstract] [Full Text] [Related]

  • 15. Secondary hyperparathyroidism in patients on maintenance hemodialysis.
    Hida M.
    Tokai J Exp Clin Med; 1982 Nov; 7(6):665-70. PubMed ID: 7184198
    [Abstract] [Full Text] [Related]

  • 16. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
    Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F.
    Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
    [Abstract] [Full Text] [Related]

  • 17. The role of quick bio-intact PTH(1-84) assay during parathyroidectomy for secondary hyperparathyroidism.
    Ikeda Y, Kurihara H, Morita N, Miyabe R, Takami H.
    J Surg Res; 2007 Aug; 141(2):306-10. PubMed ID: 17418873
    [Abstract] [Full Text] [Related]

  • 18. [Intact whole bioactive parathormone: problems arising from comparing different methods].
    Marangella M, Migliardi M, Dutto F, Mengozzi G, Marranca D, Bagnis C, Berutti S, Gallone G, Aimo G, Ramello A, Fonzo D.
    G Ital Nefrol; 2002 Aug; 19(4):467-75. PubMed ID: 12369051
    [Abstract] [Full Text] [Related]

  • 19. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL.
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [Abstract] [Full Text] [Related]

  • 20. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.
    Noordzij M, Korevaar JC, Dekker FW, Boeschoten EW, Bos WJ, Krediet RT, Bossuyt PM, Geskus RB, NECOSAD study group.
    Blood Purif; 2008 Apr; 26(3):231-7. PubMed ID: 18305386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.